Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677138 | 0.88 | ADRA1D (0.41) | MGLLADRA1DADRA1AADRA2BADRA1B | |
| SCHEMBL1764679 | 0.75 | GYS1 (0.45) | — | |
| SCHEMBL19401473 | 0.75 | GYS1 (0.45) | — | |
| SCHEMBL22550989 | 0.72 | ADRA1D (0.41) | MGLLADRA1DADRA1AADRA2BADRA1B | |
| SCHEMBL28388194 | 0.70 | HRH3 (0.44) | — | |
| SCHEMBL3937797 | 0.67 | PTGS1 (0.56) | ADRA1DADRA1AADRA2BKCNA5 | |
| SCHEMBL6166510 | 0.65 | KMT2A (0.47) | MGLL | |
| SCHEMBL28562818 | 0.65 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL23081447 | 0.65 | CREBBP (0.46) | ADRA1DADRA1AADRA2BADRA1BKCNA5 | |
| SCHEMBL1565661 | 0.65 | GRM4 (0.45) | ADRA1DADRA1AADRA2BKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111240-B2 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3434671-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111240-B2 | Sultam compound and application method thereof | IDH1, IDH3A, IDH3B | MGLL 3435/4885ADRA1D 4099/4885ADRA1A 3845/4885 |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | IDH1, IDH3A, IDH3B | MGLL 3435/4885ADRA1D 4099/4885ADRA1A 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.